

GLAXOSMITHKLINE PLC

Form 6-K

July 17, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 17 July 2018

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes  No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms E Walmsley  
Chief Executive Officer
- b) Position/status

- c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882

- a) Description of the financial instrument

- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 July 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

	Price(s)	Volume(s)
	£15.766	189
	£15.766	206
c) Price(s) and volume(s)	£15.766	721
	£15.766	189
	£15.766	206

- d) Aggregated information
- |                   |         |
|-------------------|---------|
| Aggregated volume | 1511    |
| Price             | £15.766 |

- e) Date of the transaction 2018-07-12
- f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr R G Connor
- b) Position/status President, Global Manufacturing & Supply
- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- Ordinary shares of 25 pence each ('Ordinary Shares')
- ISIN: GB0009252882

- a) Description of the financial instrument

- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 July 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
- |                           | Price(s) | Volume(s) |
|---------------------------|----------|-----------|
|                           | £15.766  | 128       |
| c) Price(s) and volume(s) | £15.766  | 107       |
|                           | £15.766  | 152       |
|                           | £15.766  | 107       |
|                           | 494      |           |
| d) Aggregated information | £15.766  |           |
| Aggregated volume Price   |          |           |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- e) Date of the transaction 2018-07-12
- f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr L Debruyne
- b) Position/status President, Global Vaccines
- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882

- a) Description of the financial instrument

- b) Nature of the transaction
- Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 July 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

	Price(s)	Volume(s)
	£15.766	180
c) Price(s) and volume(s)	£15.766	228
	£15.766	180

- d) Aggregated information
- 588
- Aggregated volume Price £15.766

- e) Date of the transaction 2018-07-12
- f) Place of the transaction London Stock Exchange (XLON)

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr S Dingemans
  - b) Position/status Chief Financial Officer
  - c) Initial notification/  
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 

Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882

- a) Description of the financial instrument

b) Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 July 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.	
	Price(s)	Volume(s)
	£15.766	249
	£15.766	187
c) Price(s) and volume(s)	£15.766	510
	£15.766	249
	£15.766	187
d) Aggregated information Aggregated volume Price	1382 £15.766	
e) Date of the transaction	2018-07-12	
f) Place of the transaction	London Stock Exchange (XLON)	

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr N Hiron
  - b) Position/status SVP, Global Ethics & Compliance
  - c) Initial notification/amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 

Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882

a) Description of the financial instrument

b) Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 July 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.	
	Price(s)	Volume(s)
	£15.766	92
	£15.766	67
c) Price(s) and volume(s)	£15.766	80
	£15.766	92
	£15.766	67
d) Aggregated information	398	
Aggregated volume Price	£15.766	
e) Date of the transaction	2018-07-12	
f) Place of the transaction	London Stock Exchange (XLON)	

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr B McNamara
  - b) Position/status CEO, GSK Consumer Healthcare
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 

American Depositary Shares ('ADSs')  
ISIN: US37733W1053

- a) Description of the financial instrument

- b) Nature of the transaction
 

Acquisition of ADSs following the re-investment of dividends paid to shareholders on 12 July 2018 on ADSs held in the Company's Deferred Annual Bonus Plan.

Price(s)	Volume(s)
\$41.75	78
\$41.75	76
- c) Price(s) and volume(s)
- d) Aggregated information
 

154  
\$41.75
- e) Date of the transaction 2018-07-12
- f) Place of the transaction New York Stock Exchange (XNYS)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr L Miels
  - b) Position/status

President, Global  
Pharmaceuticals

- c) Initial notification/  
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882

- a) Description of the financial instrument

- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 July 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

- | Price(s) | Volume(s) |
|----------|-----------|
| £15.766  | 145       |
- c) Price(s) and volume(s)

- d) Aggregated information n/a (single transaction)  
Aggregated volume Price

- e) Date of the transaction 2018-07-12
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr D S Redfern
- b) Position/status Chief Strategy Officer
- c) Initial notification/  
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted



Ordinary shares of 25 pence  
each ('Ordinary Shares')  
ISIN: GB0009252882

a) Description of the financial instrument

b) Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 July 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

	Price(s)	Volume(s)
	£15.766	117
	£15.766	85
c) Price(s) and volume(s)	£15.766	148
	£15.766	117
	£15.766	85

d) Aggregated information

Aggregated volume Price

552  
£15.766

e) Date of the transaction

2018-07-12

f) Place of the transaction

London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name

Ms K Terrell

b) Position/status

Chief Digital & Technology Officer

c) Initial notification/ amendment

Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name

GlaxoSmithKline plc

b) LEI

5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each

place where transaction(s) has been conducted

American Depositary Shares  
(‘ADSs’)  
ISIN: US37733W1053

a) Description of the financial instrument

b) Nature of the transaction Acquisition of ADSs following the re-investment of dividends paid to shareholders on 12 July 2018 on ADSs held in the Company's Deferred Annual Bonus Plan.

c) Price(s) and volume(s) Price(s) Volume(s)  
\$41.75 25

d) Aggregated information Aggregated volume Price n/a (single transaction)

e) Date of the transaction 2018-07-12

f) Place of the transaction New York Stock Exchange (XNYS)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms C Thomas

b) Position/status SVP, Human Resources

c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882

a) Description of the financial instrument

b) Nature of the transaction Acquisition of Ordinary Shares following the

re-investment of dividends  
paid to shareholders on 12  
July 2018 on Ordinary Shares  
held in the Company's  
Deferred Annual Bonus Plan.

Price(s)	Volume(s)
----------	-----------

£15.766	172
---------	-----

£15.766	128
---------	-----

c) Price(s) and volume(s)

£15.766	161
---------	-----

£15.766	172
---------	-----

£15.766	128
---------	-----

d) Aggregated information  
Aggregated volume Price

761	£15.766
-----	---------

e) Date of the transaction

2018-07-12

f) Place of the transaction

London Stock Exchange  
(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr P C Thomson
b) Position/status	President, Global Affairs
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence  
each ('Ordinary Shares')  
ISIN: GB0009252882

a) Description of the financial instrument

b) Nature of the transaction

Acquisition of Ordinary  
Shares following the

re-investment of dividends  
paid to shareholders on 12  
July 2018 on Ordinary Shares  
held in the Company's  
Deferred Annual Bonus Plan.

Price(s)	Volume(s)
----------	-----------

£15.766	105
---------	-----

c) Price(s) and volume(s)

£15.766	80
---------	----

£15.766	100
---------	-----

d) Aggregated information  
Aggregated volume Price

285	£15.766
-----	---------

e) Date of the transaction

2018-07-12

f) Place of the transaction

London Stock Exchange  
(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name

Mr D E Troy

b) Position/status

SVP & General Counsel

c) Initial notification/  
amendment

Initial notification

2. Details of the issuer, emission allowance market participant, auction  
platform, auctioneer or auction monitor

a) Name

GlaxoSmithKline plc

b) LEI

5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of  
instrument; (ii) each type of transaction; (iii) each date; and (iv) each  
place where transaction(s) has been conducted

American Depositary Shares  
(‘ADSs’)  
ISIN: US37733W1053

a) Description of the financial instrument

b) Nature of the transaction

Acquisition of ADSs  
following the re-investment  
of dividends paid to  
shareholders on 12 July 2018  
on ADSs held in the  
Company's Deferred Annual

	Bonus Plan.	
	Price(s)	Volume(s)
	\$41.75	100
	\$41.75	82
c) Price(s) and volume(s)	\$41.75	89
	\$41.75	100
	\$41.75	82
d) Aggregated information	453	
Aggregated volume Price	\$41.75	
e) Date of the transaction	2018-07-12	
f) Place of the transaction	New York Stock Exchange (XNYS)	

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: July 17, 2018

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc